Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Janssen-Cilag Pty Ltd
The primary objective of this treatment review and feedback program is to quantify the risk status for medication adherence in a cohort of Australian patients diagnosed with schizophrenia. Observational study - no study drug administered
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Clinical diagnosis of schizophrenia or schizoaffective disorder according to DSM-IV
Currently treated in an outpatient clinic
Able to provide informed consent
Concurrent enrolment in clinical trials is acceptable
Have completed all questions on the Drug Attitude Inventory (DAI-10) and Medication Adherence Rating Scale (MARS) survey
You may not be if
N/A
Clareo Health | Schizophrenia Treatment Adherence Investigation (STAI)
